There is no way Bisantrene should be bought now for anything like still below $500 million to $1billion USD market value . *Fire sale , right now , without proper consultation with major Pharma. ** POC work this year is priority . Maximise & prove potentials.
Shareholder support is strong .
The RAC board would not approve of a low buyout value . They have already been and will continue to be having communications with major pharmaceutical companies in the US and Europe .
RAC has an excellent global medical advisory team of consultants - top doctors , at some of the best oncology research and treatment facilities. eg in New York ; Prof Borje Andersson who heads the advisory team , based at MD Anderson ; and another notable haematology oncologist in France .
*RAC chairman Dr John Cullity - is a drug transaction specialist. This is his every day role - and he has his own company specialised in drug pricing and mergers and acquisition occurrences for pharmacological assets. He is a very respected Haematologist Oncologist by speciality himself as his initial specialisation after Medicine studies in Australia. He then went on to achieve Masters and speciality in business , and worked for years notably mainly for Sanofi as a head of drug pricing and acquisitions for them .
He has managed $30 billion drug acquisition deals . Dr Cullity has nearly 20 years experience exactly in this field - it is his job.
The Board members and Dr Cullity well understand the worth of Bisantrene . He thinks & thought Bisantrene was worthwhile and took a position several years ago on the Race Oncology board. He does not take high salary . None of the highly qualified board members do . Their belief is very high . The entire management team are global best standard , humble , ultra intelligent and experienced, hardworking , respected for past significant achievements, & have all lead other companies & development of initiatives including their own.
They put their energies and work only into what is worthwhile to do in life and work . I believe Dr Tillet works around the clock , and maybe they all do .
As such , re value of RAC — Dr Cullity is very committed to the very best outcome for Bisantrene & for the company . He and the entire team are excited to bring Bisantrene to a worthy buyout , beneficial to all, and most want to see bisantrene back into the clinical oncology armamentarium. RAC is working on the best pathways to final approvals . They will not undersell nor sell the company short.
The CEO , Phil Lynch , is an ex Johnson and Johnson executive and in reality has chosen to come back out of partial retirement to lead RAC . Again - high belief from all the management team.
Really a major Pharmaceutical company needs to take bisantrene through all of the possible cancer trials , likely post -approval maybe for AML .
Very strong hands in RAC as mentioned . Race is tightly held . Ultimately this will give best outcome for all . Market cap has still been too low .
Similar oncology drug deals - many with very narrow market applications , eg only for ALL , clinically have started at $1.2- $2 billion usd. ** see recent pharmaceutical deals . Bisantrene scope as even independently uncovered by City of Hope (bisantrene FTO protein inhibition , precision oncology field , & possibly or probably other cancer promoting factors inhibition also imo ) ; and over 40 clinical trials and past registered use in France — show very broad efficacy for bisantrene across a broad range of difficult to treat cancers .
Bisantrene also seems to have high specificity against dire cancers such as melanoma , renal , ovarian and breast , AML , cancers to name some of the most important cancers , with high mortality rates where bisantrene has efficacy .
, and maybe they all do .
(20min delay)